Please use this identifier to cite or link to this item:
https://repository.monashhealth.org/monashhealthjspui/handle/1/29281| Title: | Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. | Authors: | Karapetis C.S.;Price T.J.;Segelov E. ;Tebbutt N.C.;Lau D.K.;Burge M.;Roy A.;Chau I.;Haller D.G.;Shapiro J.D.;Peeters M.;Pavlakis N. | Monash Health Department(s): | Oncology | Institution: | (Lau, Chau) GI and Lymphoma Unit, Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom (Burge) Medical Oncology, Royal Brisbane Hospital, Brisbane, Australia (Burge) University of Queensland, Brisbane, Australia (Roy) Medical Oncology, Flinders Centre for Innovation in Cancer, Bedford Park, Australia (Haller) Abramson Cancer Center at the Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States (Shapiro, Segelov) Monash University, Melbourne, Australia (Shapiro) Medical Oncology, Cabrini Medical Centre, Melbourne, Australia (Peeters) Medical Oncology, University Hospital Antwerp, Edegem, Belgium (Pavlakis) Medical Oncology, Royal North Shore Hospital, St Leonards, Australia (Pavlakis) Sydney University, Camperdown, Sydney, Australia (Karapetis) Medical Oncology, Flinders Medical Centre, Bedford Park, Australia (Tebbutt) Medical Oncology, Austin Health, Heidelberg, Australia (Tebbutt) Department of Surgery, University of Melbourne, Melbourne, Australia (Segelov) Medical Oncology, Monash Medical Centre, Clayton, Australia (Price) Medical Oncology, The Queen Elizabeth Hospital, Woodville, Australia | Issue Date: | 2-May-2020 | Copyright year: | 2020 | Publisher: | Taylor and Francis Ltd | Place of publication: | United Kingdom | Publication information: | Expert Review of Anticancer Therapy. 20 (4) (pp 251-270), 2020. Date of Publication: 02 Apr 2020. | Journal: | Expert Review of Anticancer Therapy | Abstract: | Introduction: Outcomes in metastatic colorectal cancer are improving, due to the tailoring of therapy enabled by better understanding of clinical behavior according to molecular subtype. Areas covered: A review of the literature and recent conference presentations was undertaken on the topic of systemic treatment of metastatic colorectal cancer. This review summarizes expert discussion of the current evidence for therapies in metastatic colorectal cancer (mCRC) based on molecular subgrouping. Expert opinion: EGFR-targeted and VEGF-targeted antibodies are now routinely incorporated into treatment strategies for mCRC. EGFR-targeted antibodies are restricted to patients with extended RAS wild-type profiles, with evidence that they should be further restricted to patients with left-sided tumors. Clinically distinct treatment pathways based on tumor RAS, BRAF, HER2 and MMR status, are now clinically applicable. Evidence suggests therapy for additional subgroups will soon be defined; the most advanced being for patients with KRAS G12 C mutation and gene TRK fusion defects.Copyright © 2020, © 2020 Informa UK Limited, trading as Taylor & Francis Group. | DOI: | http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1080/14737140.2020.1744439 | PubMed URL: | 32186929 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32186929] | ISSN: | 1473-7140 | URI: | https://repository.monashhealth.org/monashhealthjspui/handle/1/29281 | Type: | Review | Subjects: | encorafenib/dt [Drug Therapy] erlotinib/dt [Drug Therapy] fluoropyrimidine/dt [Drug Therapy] fluorouracil/ae [Adverse Drug Reaction] fluorouracil/dt [Drug Therapy] folinic acid/ae [Adverse Drug Reaction] folinic acid/dt [Drug Therapy] gimeracil plus oteracil potassium plus tegafur/dt [Drug Therapy] irinotecan/ae [Adverse Drug Reaction] irinotecan/dt [Drug Therapy] mitomycin/dt [Drug Therapy] oxaliplatin/ae [Adverse Drug Reaction] oxaliplatin/dt [Drug Therapy] panitumumab/dt [Drug Therapy] ramucirumab/dt [Drug Therapy] tipiracil plus trifluridine/ae [Adverse Drug Reaction] tipiracil plus trifluridine/dt [Drug Therapy] trametinib/dt [Drug Therapy] BRAF gene HER2 gene KRAS gene NTRK gene mrtx 849 vemurafenib/dt [Drug Therapy] cancer chemotherapy diarrhea/si [Side Effect] evidence based medicine febrile neutropenia/si [Side Effect] gene gene amplification gene expression gene mutation human medical expert medical specialist *metastatic colorectal cancer/dt [Drug Therapy] microbiome mismatch repair neutropenia/si [Side Effect] overall survival review signal transduction aflibercept/dt [Drug Therapy] bevacizumab/dt [Drug Therapy] capecitabine/dt [Drug Therapy] cetuximab/dt [Drug Therapy] circulating tumor DNA/ec [Endogenous Compound] dabrafenib/dt [Drug Therapy] encorafenib erlotinib fluoropyrimidine fluorouracil folinic acid gimeracil plus oteracil potassium plus tegafur irinotecan mitomycin oxaliplatin panitumumab ramucirumab tipiracil plus trifluridine trametinib BRAF gene HER2 gene KRAS gene NTRK gene mrtx 849 vemurafenib cancer chemotherapy diarrhea evidence based medicine febrile neutropenia gene gene amplification gene expression gene mutation medical expert medical specialist metastatic colorectal cancer microbiome mismatch repair neutropenia signal transduction aflibercept bevacizumab capecitabine cetuximab circulating tumor DNA dabrafenib medical specialist *metastatic colorectal cancer / *drug therapy microbiome mismatch repair neutropenia / side effect overall survival Review diarrhea / side effect cancer chemotherapy signal transduction evidence based medicine febrile neutropenia / side effect gene gene amplification gene expression gene mutation human medical expert |
Type of Clinical Study or Trial: | Review article (e.g. literature review, narrative review) |
| Appears in Collections: | Articles |
Show full item record
Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.